Tech Company Financing Transactions
Vivere Oncotherapies Funding Round
Vivere Oncotherapies closed a $10 million funding round on 1/14/2026. Investors included Backers, Berkeley Frontier Fund and FreeFlow.
Transaction Overview
Company Name
Announced On
1/14/2026
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2630 Bancroft Way
Berkeley, CA 94720
US
Berkeley, CA 94720
US
Phone
Undisclosed
Website
Email Address
Overview
Vivere is developing next-generation cancer therapies aimed at activating the immune system to selectively detect and destroy cancer cells in cold tumors that otherwise remain hidden to the body's natural defenses. Our name Vivere (pronounced VEE-veh-ray) means "to live" and reflects our mission to develop life-saving treatments for patients by applying innovative engineering approaches to solve complex human biology challenges.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Melissa Kotterman
Co-Founder
John Dueber
Co-Founder
Hyuncheol Lee
Co-Founder
Wanichaya Noiwangklang
Co-Founder
David Schaffer
Co-Founder
Adam Schieferecke
Browse more venture capital transactions:
Prev: 1/14/2026: Meet Caria venture capital transaction
Next: 1/14/2026: Caldera Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs